Camlin Fine Sciences: No Deviation in Rights Issue Fund Utilization for Q4 2025
Camlin Fine Sciences' Monitoring Agency Report for Q4 2025 confirms no deviation in Rights Issue fund utilization. Total funds were ₹22,468.87 Lakhs. Key uses include debt repayment and general corporate purposes. Unutilized funds are in FDs. A 9-month delay is noted for General Corporate Purposes.
This is a post-issuance compliance report that confirms adherence to the original plan. It does not introduce new material information that would significantly affect the company's stock price or investor perception.
The report is a routine update confirming no deviation in the utilization of funds from a past rights issue. It does not contain any new financial performance data or forward-looking statements that would indicate a positive or negative shift.
Camlin Fine Sciences Limited has submitted its Monitoring Agency Report for the quarter ended December 31, 2025, regarding the utilization of funds raised through its Rights Issue. The report, prepared by India Ratings & Research Private Limited, was reviewed and approved by the company's Audit Committee and Board of Directors on February 13, 2026.
The company confirmed that there has been no deviation in the utilization of the Rights Issue proceeds from the objects stated in the Letter of Offer. The total issue size was ₹22,468.87 Lakhs, with ₹22,468.39 Lakhs effectively received after accounting for shares kept in abeyance.
Key utilization areas included prepayment/repayment of borrowings (₹15,747.56 Lakhs), General Corporate Purposes (₹4,672.26 Lakhs), and Issue related expenses (₹69.24 Lakhs). A portion of the originally allocated issue expenses (₹129.50 Lakhs) was reallocated to General Corporate Purposes as these expenses were met prior to the receipt of issue proceeds.
Unutilized funds totaling ₹2,0489.06 Lakhs were deployed primarily in Fixed Deposits with the State Bank of India, earning annualized returns ranging from 3.05% to 6.75%. A significant portion of the unutilized funds, ₹1,598.83 Lakhs, is allocated for General Corporate Purposes in FY 2026.
The report also noted a delay of 9 months for the General Corporate Purposes object, with the company continuing to utilize funds for this purpose in FY 2026. An investment of ₹145.97 Lakhs was made in Clean Max Sundarban Private Limited for captive solar power generation under General Corporate Purposes.
What to do with a filing like this
Camlin Fine Sciences Limited filed this with the NSE as a statutory disclosure, categorised under rights issue. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Camlin Fine Sciences Limited. Read the original for the full detail.